Trial Profile

A Phase 2,Multi-center, Open-label Study Evaluating Safety and Efficacy of Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Dec 2023 Results (At the data cutoff of June 30, 2022) assessing Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002 for Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition
11 Dec 2023 According to a Zelgen media release, results from this trial were presented at the 65th American Society of Hematology (ASH) Annual Meeting 2023.
11 Dec 2023 Long-term follow-up results presented in the Zelgen Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com